Edgewise Therapeutics (EWTX) said Wednesday that the latest results from a phase 2 trial of EDG-7500 showed "rapid and clinically meaningful reductions" in left ventricular outflow tract gradients in participants with obstructive hypertrophic cardiomyopathy.
A four-week treatment with EDG-7500 also showed "substantial improvements" in measures of feel and function, as well as reductions in key cardiac biomarkers and positive trends in measures of diastolic function, the company said.
Edgewise said the initial data read-out from the study's part D is expected in H2 2025, while the phase 3 study is planned to begin in H1 2026.
Hypertrophic cardiomyopathy is a form of genetic heart disease.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。